Bezlotoxumab (Zinplava®)

Covered: a single IV dose of bezlotoxumab (Zinplava) up to 10 mg/kg to reduce recurrence of C. difficile infection only for patients actively receiving antibacterial therapy for CDI and who are at high risk for recurrence; not covered for patients who have previously received bezlotoxumab or who are not receiving antibacterial therapy or not high‑risk. Key requirements: documentation of antibacterial treatment, high‑risk status, no prior bezlotoxumab, administered dose/route and that only one IV dose was given, plus adherence to the policy’s coverage guidelines and safety criteria.

"To reduce the recurrence of Clostridium difficile infection (CDI) in individuals who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence."

Sign up to see full coverage criteria, indications, and limitations.